Neural stem cell-mediated delivery of oncolytic adenovirus

Julius W. Kim, J. Robert Kane, Jacob S. Young, Alan L. Chang, Deepak Kanojia, Shuo Qian, Drew A. Spencer, Atique U. Ahmed, Maciej S. Lesniak

Research output: Contribution to journalArticlepeer-review

3 Scopus citations


The use of stem cells (SCs) as carriers for therapeutic agents has now progressed to early clinical trials. These clinical trials exploring SC-mediated delivery of oncolytic adenoviruses will commence in the near future, hopefully yielding meritorious results that can provoke further scientific inquiry. Preclinical animal studies have demonstrated that SCs can be successfully loaded with conditionally-replicative adenoviruses and delivered to the tumor, whereupon they may evoke pronounced therapeutic efficacy. In this protocol, we describe the maintenance of SCs, provide an analysis of optimal adenoviral titers for SC loading, and evaluate the optimized viral loading on SCs.

Original languageEnglish (US)
Pages (from-to)13.11.1-13.11.9
JournalCurrent protocols in human genetics
StatePublished - 2015


  • Cancer
  • Gene therapy
  • Mesenchymal stem cell
  • Neural stem cell
  • Oncolytic adenovirus

ASJC Scopus subject areas

  • Genetics
  • Genetics(clinical)


Dive into the research topics of 'Neural stem cell-mediated delivery of oncolytic adenovirus'. Together they form a unique fingerprint.

Cite this